[QODLink]
Central & South Asia
India ruling on cancer drug to be challenged
Order forcing Bayer to license its product to local company has huge repercussions for pharmaceutical giants.
Last Modified: 15 Mar 2012 04:50



A patent ruling in India is forcing German drug giant Bayer to license its anti-cancer medicine to an Indian company, Natco.

This will slash the price of the drug in India by up to 97 per cent. Bayer insists it will fight the ruling although Natco will be paying it six per cent royalty on the sales of Nexavar.

This is the first time such a ruling has been made in India and has massive repercussions for drug giants and their patents globally.

Prerna Suri reports from New Delhi.
Source:
Al Jazeera
Topics in this article
Country
City
Organisation
Featured on Al Jazeera
Al Jazeera's exclusive publishing of a key Guantanamo prison military document lays bare the brutality of force-feeding.
Former military official says poverty and anger in indigenous communities mean conditions for an "insurgency" are ripe.
A four-part series that gives a rare insight into the country on the move, with history in tow.
Series on the Palestinian 'catastrophe' of 1948 that led to dispossession and conflict that still endures.
Featured
Somalia ghost town
Once a bustling haven, Elasha Biyaha has almost become a ghost town as residents flee.
Syria: The War Within
Two years since the start of the uprising, rebels and Assad's forces remain locked in conflict.
China Rising
A four-part series that gives a rare insight into the country on the move, with history in tow.
Crisis in Bangladesh
Extensive coverage of war crimes tribunals and controversial calls for blasphemy laws.
Al-Nakba
Series on the Palestinian 'catastrophe' of 1948 that led to dispossession and conflict that still endures.
join our mailing list